guidanc industri irrit bowel syndrom clinic evalu drug treatment us depart health human servic food drug administr center drug evalu research cder may 2012 clinicalmed guidanc industri irrit bowel syndrom clinic evalu drug treatment addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10903 new hampshir ave bldg 51 rm 2201 silver spring md 209930002 tel 3017963400 fax 3018478714 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder may 2012 clinicalmed tabl content introduct 1 ii background 2 iii evolut pro measur ib clinic trial 2 iv provision endpoint trial design ib clinic trial 4 1 trial design 4 2 trial endpoint 5 3 trial popul 6 4 efficaci asur 7 5 definit respond 7 v futur develop ib pro instrument 11 vi conclus 11 refer 12 contain nonbind recommend guidanc industry1 irrit bowel syndrom clinic evalu drug treatment guidanc repres food drug administrati on fda current think topic creat confer right pe rson oper bind fda public use altern approach approach satisfi requir applic statut regul want discuss alterna tive approach contact fda staff respons implement guidanc identifi appropri fda staff call appropri number list titl page guidanc introduct guidanc intend assist pha rmaceut industri investig develop drugs2 treatment irrit bowel syndrom ib ib diagnosi assess clinic statu depend mainli evalu ib sign symptom known patient captur clinic alli import sign symptom associ ib reliabl measur treatment benefit challeng ing guidanc industri patientreport outcom measur use medic product develop support label claim pro guidance3 defin term treatment benefit effect treatment patient surviv feel function guidanc address two main topic sectio n iii discuss evolut patientreport outcom pro measur primari endpoint ib clinic trial section iv provid set provision endpoint trial design commend sponsor may appli ib clinic trial pro measur continu evolv guidanc also discuss section v futur develop ib pro instru ment fda qualif process fda collabor critic path institut recommend provid guidanc consist good measur scie nce reflect fda guidanc 1 guidanc prepar divis gastroenterolog inborn error product studi endpoint label develop team center drug evalu research cder food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 contain nonbind recommend goal efficaci endpoint ib clinic trial assess treatment effect core diseasedefin sign symptom ib welldefin reliabl way endpoint avail provi sional endpoint assess sugg sted guidanc use evalu treatment benefit ib clinic trial guidanc appli ib indic ib diarrhea ibsd ib constip ibsc sponsor contac divis gast roenterolog inborn error product discuss endpoint assessm ent trial design propos ib popul discuss guidanc ie mix irrit bowel syndrom unsubtyp irrit bowel syndrom fda guidanc document includ guid anc establish legal enforc respons instead guidanc describ th e agenc current thinki ng topic view recommend unless spec ific regulatori stat utori requir cite use word agenc guidanc mean someth suggest recommend requir ii background ib complex condit well link readili measur physiolog abnorm despit advanc understandi ng basic neuroenter mechan role effector transmitt braingut axi reliabl biolog marker ib yet indentifi 4 pro measur sign symptom condit current avail measur adequ de fine treatment effect clinic trial iii evolut pro measur ib clinic trial adequ measur trea tment benefit captur th e signific sign symptom ib primari challeng designi ng clinic trial evalu efficaci drug condit defin critic sign sy mptom relev patient select develop adequ assess tool measur improv decrement import ant sign symptom past ib clinic trial commonli use singleitem patientreport rate overal chang condit primari efficaci endpoint5 singleitem patientreport rate chang use primari endpoint specif ib sign symptom often includ separ secondari endpoint detail tabl 1 exampl singleitem patientreport rate ch ang includ questi on pose patient adequ relief satisfactori relief singl item subject global assessmen relief ib symptom usual patientreport rate chang requir patient averag either specif symptom eg abdomin pain discom fort sign symptom ib 4 see refer number 18 referenc es section end guidanc 5 see refer number 923 refer nce section end guidanc 2 contain nonbind recommend week time compar averag period past typica lli trial entri tabl 1 describ primari endpoint use sever ib clinic trial although endpoint may well captur dire ction chang trial control blind could provid use informati effect treatm ent sever specif sign symptom tabl 1 primari endpoint use ib clinic trial drug indic primari endpoint question singleitem use assess efficaci respons alosetron adequ relief past 7 day adequ relief binari yesno ibsd 1 ib pain discomfort tegaserod satisfactori satisfactori relief overal ib binari yesno ibsc2 relief subject global assess relief sga symptom last week satisfactori relief abdomin discomfort pain last week pleas consid felt past treatment period regard ib particular overal wellb symptom abdomin paindiscomfort alter bowel habit compar way usual felt enter trial would rate relief symptom past week binari yesno 5point likert scale lubiproston modifi would rate relief ib symptom 7point likert scale ibsc 3 version sga abdomin discomfortpain bowel habit ib symptom past week compar felt enter trial 1 see refer number 914 refer section end guidanc 2 see refer number 1522 refer section end guidanc 3 see refer number 23 refer section end guidanc note pro guidanc defin treatment benefit effect treatment patient surviv feel function pro instrument defin captur patient perspect respect th e diseas condit inter st appropri measur effect treatment clinic trial particularli desir effect treatment sign symptom known patient consist fda regul drug approv effect treat ment must base substanti evid includ evid method assess subject respons welldefin reliabl 21 cfr 314126b6 pro guidanc set forth fda review principl determin whether assess welldefin ie valid adequ develop ie reliabl sensit interpret measur intend measur reflect pro guidanc type pro instrument consid appropri data collect support label claim evolv consid appropri past exampl longer recommend singl gener item ask patient rate chang overal ib symptom primari endpoi nt support efficaci claim singl gener item adequ cap ture whether benefit achiev import sign symptom exampl si ngle item queri patient 3 contain nonbind recommend overal ib experi like captur situat patient stool frequenc improv abdomin pain improv even worsen recognit limit use si ngleitem patientreport rate overal chang primari endpoint base principl es explain pro guidanc recommend develop multiitem pr instrument pro measur captur clinic import sign symptom ib target popul eg ibsc ibsd chang previou score calcul drug develop specif improv one major si gn symptom ib eg abdomin pain base drug mechan action still import assess import sign symptom document drug neg affect compon ultim drug indic reflect find clinic trial iv provision endpoint tr ial design ib clinic trial welldefin reliabl pro instrument measur clinic import sign symptom associ ib subtyp would ideal pr imari efficaci assess tool clinic trial use support label claim time instrument avail recogn take time develop ad equat instrument meantim great need develop effect therapi patient ib therefor appropri pro instrument develop sponsor consid strategi discuss follow section design ib c linic trial section set forth provision sta ndard regard 1 tria l design 2 tria l endpoint 3 trial popul 4 efficaci measur 5 definit respond follow discuss tabl 2 summ ariz provision standard ibsc ibsd trial design includ primari endpoint patient entri criteria respond definit tabl 2 intend summari discuss guidanc sponsor refer text guidanc full detail 1 trial design clinic sign symptom associat ed ibsc ibsd significantli differ two condit ordi narili studi separ clinic trial random placebocontrol trial design shoul includ 1 2week singleblind openlabel screen period 1 2week screen period use establish presenc persist tria l entri criteria train patien ts mode pro data collect select trial screen period also use select patient specifi level sever sign sympto ms therapi administ chronic continu basi recommend treatment period least 8 week durat follow random withdraw design ddress need mainten treatment prevent sign symptom recurr 4 contain nonbind recommend therapi intermitt administra tion schedul sponsor provid repeat cours therapi demonstr sustain effi caci time character safeti intermitt repeat administr 2 trial endpoint support indic treatment ib recommend primari endpoint measur effect treatment tw major ib sign symptom abnorm defec abdomin pain6 primari efficaci analysi comparison respons rate investig drug placebo ibsc defec compon pr opos primari endpoint evalu assess stool frequenc stool frequenc measur number complet spontan bowel movement csbm per week readili de fine use defin treatment respons chronic constip c linic trial clinic relev ibsc patient ibsd defec compon pr opos primari endpoint evalu assess stool consistency7 bristol stool form scale reproduc figur 1 provid pictori verbal de scription stool consist nd form appropri instrument captur stool consist ib trials8 figur 1 bristol stool form scale 6 see refer number 24 refer section end guidanc 7 see refer number 25 26 refer section end guidanc 8 see refer number 27 refer section end guidanc 5 contain nonbind recommend stool frequenc evalua ted key secondari endpoint use weekli number csbm stool consist rather stool frequenc recomm end primari endpoint ibsd clinic alli relev better correla ted sign symptom diarrhea current insuffici data adequ quantifi qualifi concept urgenc base patient perspect th us support use compon primari endpoint definit treatment respons adequ urgenc assess tool develop stool urgenc assess explor endpoint ibsd trial second compon primari endpoint ibsc ibsd trial abdomin pain although previou ib clinic trial use item assess abdomin pain discomfort clear whether th e abdomin pain abdomin discomfort experienc patient ib synonym two differ nt symptom although adequ qualit trial fulli address question clinic data provid review fda suggest abdomin pain discomfort may differ symptom assess differ question frank pain seem symptom experienc signific intens discomfort chronic pa literatur suggest pain intens may clinic ly relev assess pain frequency9 recommend abdomin pain intens prim ari pain assess ib trial abdomin discomfort evalu secondari endpoint recommend evalu abdomin pain intens use 11point e 0 10 numer rate scale ask pati ent daili rate worst abdomin pain past 24hour 10 type pain assess use assess pain somat viscer neuropath chronic pain conditions11 drug specif develop treat one major sign symptom ib identifi primari endpoint clinic trial identif singl sign symptom interest ba sed mechan action drug key efficaci endpoint assess clinic trial secondari endpoint demonstr signific clinic mean ing chang target singl endpoint could serv basi approv long import symptom sign worsen treatment 3 trial popul base upon evolut ib diagnost crit eria prospect ib c linic trial enrol patient meet subtyp specif rome iii ib diagnost criteria12 addit patient enter trial clinic manifest ib assess 9 see refer number 28 refer section end guidanc 10 see refer number 28 29 refer section end guidanc 11 see refer number 30 refer section end guidanc 12 see refer number 25 refer section end guidanc 6 contain nonbind recommend trial defin treatment respons manifest present suffici intens make demonstr clinic eaning improv possibl light compon primari endpoint ibsc nd ibsd previous de scribe recommend trial entri criteria includ follow ibsc abdomin pain intens weekli averag worst daili past 24 hour abdomin pain score 30 0 10 point scale stool frequenc fewer three csbm per week ibsd abdomin pain intens weekli averag worst daili past 24 hour abdomin pain score 30 0 10 point scale stool consist least one stool consi tenci type 6 type 7 bristol stool score bss least 2 day per week 4 efficaci measur sponsor choos format daili sign symptom assess eg interact voic respons person digit assist ant patient evalua te ib sign symptom daili basi throughout tr ial assess respons sponsor consid two distinct approach 1 examin differ nce averag score averag chang baselin score tr eat untreat group 2 examin differ respons rate treat untreat group respons prospect defin repres effect consid ere clinic meaning mani instanc effect drug effect measur 5 definit respond definit respond use analys primari endpoint prospect describ protocol st atist analysi plan pati ent categor overal respond patient achiev prespecifi improv weekli daili respons least 50 percent week day treatment eg 612 week 4284 day recommend defin weekli daili respons ib set follow 7 contain nonbind recommend ibsc13 patient categor weekli respond patient weekli respond pain intens stool frequenc abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdomin pain past 24 hour score measur daili least 30 percent co mpare baselin weekli averag stool frequenc weekli respond de fine patient experi increas least one csbm per week baselin ibsd patient categor weekli respond patient weekli respond pain intens stool consist abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdomin pain past 24 hour score least 30 percent compar ed baselin stool consist weekli respond defin patient experi 50 percent greater reduct number day per week least one stool consist type 6 7 compar baselin patient categor daili respond patient respond pain intens stool consist abdomin pain intens daili respond defin patient experi decreas worst abdomin pain past 24 hour score least 30 percent compar baselin stool consist daili respond defi ned patient whose stool consist ie bss less 5 fo r bowel movement day bowel movement ibsd either weekli respond da ili respond definit may accept drug intend target one major ib sign symptom base mechan action recommend follow respond definit abdomin pain ibsc abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdo minal pain past 24 hour score least 30 percent compar baselin st ool frequenc ibsc unchang improv compar baselin 13 ibsc patient daili bowel movement even though abdomin pain may occur frequent daili respons criteria relev patient popul 8 contain nonbind recommend abdomin pain ibsd abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdo minal pain past 24 hour score least 30 percent compar baselin number da ys per week least one stool consist type 6 7 baselin decreas number stool type 6 7 hose day remain unchang decreas abdomin pain intens daili respond defin patient experi decreas worst abdomin pain past 24 hour score least 30 percent compar baselin whose stool con istenc day less 5 bowel movement bowel movement constip ibsc stool frequenc respond defin patient experi increas least one csbm per week baselin nd abdomin pain unchang improv compar baselin diarrhea ibsd stool consist respond defin patient experien ce 50 percent greater reduct number day least one st ool consist type 6 7 compar baselin bdomin pain unchang improv comparison baselin respond definit describ guidanc support adequ content valid unclear repres clinic ly meaning chang abdomin pain abnorm defec patient ib abdomin pain respond definit greater equal 30 pe rcent reduct abdomi nal pain intens compar baselin primarili base publish literatur concern chr onic pain conditions14 therefor recommend conduct addit respond anal yse evalu greater reduct abdomin pain intens treatment ie greater equal 40 andor 50 percent reduct abdomin pain intens compar baselin addit would use examin cumul distribut sever gnitud abdomin pain intens reduct associ treatment eg 30 percent 40 pe rcent 50 percent well particular reduct eg 100 percent pain intens reduct secondari endpoint although recommend pa tient rate chang primari endpoint singl gener item adequ captur th e treatment effect clinic import sign symptom ib us eful defin clini calli meaning chang anoth measur anchorbas appr oach relat chang score measur differ specif measur its lf therefor r ecommend includ patient rate chang anchor exploratori endpoint conjunct endpoint includ guidanc global assess k patient evalu current ib 14 see refer number 31 refer section end guidanc 9 contain nonbind recommend statu compar current ib sign symptom anoth point time baselin statu exampl assess includ follow question could ask patient weekli basi would rate abdomin pa overal th e past 7 day would rate constip ib sc diarrhea ibsd overal past 7 day would rate ib sign sy mptom overal past 7 day sponsor consid likert scale respons option 2 significantli reliev 1 moder reliev 0 unchang 1 moder wors 2 significantli wors tabl 2 summari recommend provis al primari endpoint entri criteria respond definit indic primari endpoint entri criteria respond definit ibsc abdomin pain intens stool frequenc abdomin pain intens weekli averag worst abdomin pain past 24 hour score 30 0 10 point scale stool frequenc 3 csbm per week abdomin pain intens decreas weekli averag worst abdomin pain past 24 hour score least 30 compar baselin stool frequenc increas 1 csbm per week compar baselin ibsd abdomin pain intens stool consist abdomin pain intens weekli averag worst abdomin pain past 24 hour score 30 0 10 point scale stool consist least 2 day per week least one stool consist type 6 type 7 bss see figur 1 detail abdomin pain intens weekli respond defin decreas weekli averag worst abdomin pain past 24 hour score least 30 compar baselin daili respond defin decreas worst abdomin pain past 24 hour score least 30 compar baselin stool consist weekli respond defin decreas least 50 number day per week least one stool consist type 6 7 compar baselin daili respond defin patient whose stool consist less 5 bowel movement day bowel movement drug may design improv one major sign symptom ib detail pleas refer discuss section iv guidanc 10 contain nonbind recommend v futur develop ib pro instrument octob 2010 publish th e draft guidanc industri qualif process drug develop tools15 drug develop tool ddt intend ed potenti use time multipl drug develop program includ limit biomark clinic outcom assess includ pro instrument fda qualif conclus within state context use result assess ddt reli upon specif interpret app licat drug develop regulatori decisionmak qualif process provid effici ent mean ddt develop qualif requir signific work form ation collabor group may lessen resourc burden upon individu al compani one collabor group pro consortium form 2008 critic path institut publicpriv partnership pro consortium charg task effi cientli collabor develop reliabl interpret instrument avail public domain sponsor use medic product clinic trial collabor includ mber fda industri academia profession organ patient advo caci group government agenc addit inform pro consortium found httpwwwcpathorg activ particip pro consor tium other consult advic stage qualif develop pro measur sign symptom ibsc ibsd qualifi ib subtypespecif pro measur replac provision endpoint describ guidanc fda recommend measur treatment benefit use ibsc ibsd clinic trial vi conclus provision endpoint trial design reco mmendat guidanc current accept use evalu drug fo r treatment ibsd ibsc recommend assist drug develop develop treatment address need patient ib import work develop welldefin reliabl pro instrument fda qualif continu 15 final guidanc represen fda current think topic recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationguid ancesdefaulthtm 11 contain nonbind recommend refer 1 mayer ea bradesi l chang et al 2008 function gi disord anim model drug develop gut 57384404 2 camilleri nj talley 2004 pathophysiol ogi basi understand symptom complex therapeut target neurogastroenterol motil 16135142 3 andresen v vm montori j keller et al 2008 effect 5hydroxytryptamin serotonin type 3 antagonist symptom relief constip nonconstip irrit bowel syndrom systemat review metaana lysi random control trial clin gastroenterol hepatol 6545555 4 heaton kw j radvan h cripp et al 1992 defec frequenc time stool form gener popul prospect studi gut 33818824 5 horikawa h mieno inou et al 1999 gastrointestin motil patient irrit bowel syndrom studi use radi opaqu marker scand j gastroenterol 3411901195 6 sadik r po stotzer simrn et al 2008 gastrointestin transit abnorm frequent detect patient unexplain gi symptom tertiari centr neurogastroenterol motil 20197205 7 gorard da gw libbi mj farth 1995 effect tricycl antidepress small intestin motil health diarrhea predomin irrit bowel syndrom dig di sci 408695 8 camilleri l chang 2008 challeng therapeut pipelin irrit bowel syndrom end point regul hurdl gastroenterolog 13518771891 9 jone rh g holtmann l rodrigo et al 199 9 alosetron reliev pain improv bowel function compar mebeverin fema le nonconstip ib patient aliment pharmacol ther 1314191427 10 camilleri ea mayer da drossman et al1999 improv pain bowel function femal ib alosetron 5ht3 receptor antagonist aliment pharmacol ther 1311491159 11 camilleri ar northcutt kong et al 2000 efficaci safeti alosetron women ib randomis placeboc ontrol trial lancet 35510351040 12 camilleri wy chey ea mayer et al 20 01 random control clinic trial serotonin type 3 receptor antagonist alosetr women diarrheapredomin ib arch intern med 16117331740 12 contain nonbind recommend 13 chey wd wy chey heath et al 2004 l ongterm safeti efficaci alosetron women sever diarrheapredomin ant ib j gast roenterol 9921952203 14 chang l vz ameen ge duke et al 2005 doserang phase ii studi efficaci safeti alosetron men diarrhea predomin ib j gastroenterol 100115123 15 kellow j oy lee fy chang et al 2003 asiapacif doubleblind placebo control random studi evalu effi caci safeti toler tegaserod patient ib gut 52671676 16 nyhlin h c bang j elsborg et al 2004 doubleblind placebo control random studi evalu efficaci safeti tolerab iliti tegaserod patient ib scand j gastroenterol 39119126 17 mullerlissn g holtmann p rueegg et al 2005 tegaserod eff ectiv initi retreat ib constip aliment pharmacol ther 211120 18 tack j mullerlissn p bytzer et al 2005 random control trial assess efficaci safeti repeat tegaserod therapi women irrit bowel syndrom constip gut 5417071713 19 fri c begling n gilgen bobalj et al 2005 tegaserod safe welltoler effect treatment patient n ondiarrhea ib eur j gastroenterol hepatol 17421427 20 novick j p miner r kraus et al 2002 random doubleblind placebocontrol trial tegaserod femal patient sufferi ng ibsc aliment pharmacol ther 161877 1888 21 mullerlissn sa fumag kd bardha n et al 2001 tegaserod 5ht4 receptor partial agonist reliev symptom ib patient abdomin pain bloat constip aliment pharmacol ther 1516551666 22 mullerlissn g koch nj talley et al 2004 subject global assess relief appropri method assess impact treatment ibsrel symptom clinic trial j clin epidemiol 56310316 23 drossman da w chey r pana et al 2007 lubiproston significantli improv symptom relief rate adult ib gastroenterolog 13225862587 24 longstreth gf wg thompson wd che la houghton f mearin rc spiller 2006 function bowel disord ga stroenterolog apr1305148091 25 rome endpoint outc ome confer 2009 httpwwwromecriteriaorgmeetin gseventsendoutconfprogramcfm 13 contain nonbind recommend 26 talley nj 2009 green light fda fo r new drug develop irrit bowel syndrom function dyspepsia j gastroenterol 10413391341 27 lewi sj kw heaton 1997 stool form scal e use guid intestin transit time scand j gastroenterol 3299204 28 turk dc rh dworkin et al 2003 core ou tcome domain chronic pain clinic trial immpact recommend pain 106337345 29 cleeland cs km ryan 1994 pain assess global use brief pain inventori ann academ medicin 232129138 30 dworkin rh et al 2005 core outcom measur chronic pain clinic trial immpact recommend pain 113919 31 dworkin rh et al 2008 interpret clin ical import treatment outcom chronic pain clinic trial immp act recommend pain 92105121 14 6212019